Specify a stock or a cryptocurrency in the search bar to get a summary
Veracyte Inc
VCYTVeracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Address: 6000 Shoreline Court, South San Francisco, CA, United States, 94080
Analytics
WallStreet Target Price
42 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures VCYT
Dividend Analytics VCYT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History VCYT
Stock Valuation VCYT
Financials VCYT
Results | 2019 | Dynamics |